MPM Bioimpact LLC Raises Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

MPM Bioimpact LLC grew its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 57.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 236,213 shares of the medical equipment provider's stock after acquiring an additional 86,031 shares during the quarter. Lantheus comprises 3.0% of MPM Bioimpact LLC's portfolio, making the stock its 8th biggest position. MPM Bioimpact LLC owned about 0.34% of Lantheus worth $21,132,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Lantheus by 47.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider's stock valued at $1,041,000 after buying an additional 3,772 shares in the last quarter. Empirical Asset Management LLC acquired a new stake in shares of Lantheus in the fourth quarter valued at about $323,000. Focus Financial Network Inc. acquired a new stake in shares of Lantheus in the fourth quarter valued at about $292,000. Janney Montgomery Scott LLC grew its stake in shares of Lantheus by 40.9% in the fourth quarter. Janney Montgomery Scott LLC now owns 19,806 shares of the medical equipment provider's stock valued at $1,772,000 after buying an additional 5,753 shares in the last quarter. Finally, Van ECK Associates Corp grew its stake in shares of Lantheus by 31.7% in the fourth quarter. Van ECK Associates Corp now owns 76,996 shares of the medical equipment provider's stock valued at $6,888,000 after buying an additional 18,524 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Insiders Place Their Bets

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. This trade represents a 8.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 63,109 shares of company stock valued at $6,016,046 over the last three months. Company insiders own 1.50% of the company's stock.

Lantheus Stock Up 1.8%

NASDAQ:LNTH traded up $1.46 during trading hours on Friday, reaching $81.24. 913,883 shares of the stock were exchanged, compared to its average volume of 981,392. The firm has a 50 day simple moving average of $97.11 and a 200-day simple moving average of $93.31. Lantheus Holdings, Inc. has a 52 week low of $75.00 and a 52 week high of $126.89. The stock has a market capitalization of $5.62 billion, a P/E ratio of 13.52 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The company had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company's revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.69 EPS. As a group, analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on LNTH. StockNews.com upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. B. Riley lowered their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. Finally, Truist Financial lowered their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $132.67.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.